Walgreens Boots Alliance, Inc. (NASDAQ: WBA) has been struggling to keep up gross sales momentum and profitability for fairly a while because of a difficult working surroundings. The principle headwinds to the enterprise are inflation-induced pressure on client spending and unfavorable market dynamics. Contemplating these elements, market watchers have issued not-so-optimistic estimates for the August quarter.
The market’s disappointment over Walgreens’ lack of ability to remain resilient is seen within the efficiency of its inventory. WBA is among the worst-performing shares that always underperformed the trade and the broad market in current instances. Final month, the shares slipped into the single-digit territory for the primary time in additional than twenty years. The worth has plunged round 67% to date this 12 months.
The Deerfield-headquartered retail pharma big is ready to publish its fourth-quarter report on Tuesday, October 15, at 7:00 am ET. The consensus earnings estimate for the ultimate three months of fiscal 2024 is $0.36 per share, which is sharply decrease than the $0.67 per share the corporate earned within the prior-year quarter. Gross sales are anticipated to extend modestly to $35.75 billion within the fourth quarter from $35.42 billion a 12 months earlier.
Slowdown
With household budgets coming beneath stress from the financial slowdown, Walgreens’ clients have turn into more and more price-conscious. The scenario has compelled the corporate to introduce promotional provides and reductions, which in flip put stress on near-term profitability. In the meantime, the corporate has initiated measures to make its enterprise mannequin sustainable, corresponding to renegotiating incentives with companions and partnering straight with pharma corporations to reap the benefits of its distinctive place available in the market.
Walgreens and its friends like CVS Well being have been going through stiff competitors from Amazon ever because the latter entered the pharmacy retail house with the acquisition of PillPack about six years in the past. Whereas persevering with its efforts to spice up retailer visitors, Walgreens has revealed plans to shut practically a fourth of its shops, with a deal with unprofitable areas, because the shift to on-line prescriptions continues.
Within the three months ended Might 31, 2024, Walgreens’ gross sales grew throughout all three working segments, driving up the entire to $36.4 billion. Comparable pharmacy gross sales rose 5.7% year-over-year, whereas comparable retail gross sales dropped 2.3%. Excluding particular objects, third-quarter earnings decreased to $0.63 per share from $1.00 per share a 12 months earlier, primarily reflecting decrease sale-leaseback good points and softness in retail and pharmacy efficiency.
Outlook
In the meantime, reported revenue greater than doubled to $344 million or $0.40 per share throughout the three months, aided by a lower in SG&A bills. Earnings missed Road View whereas revenues nearly matched estimates, after beating within the trailing two quarters. In an indication that the pressure on profitability has prolonged into the second half, the Walgreens management forecasts adjusted earnings per share within the $2.80-2.95 vary for fiscal 2024, which is under the prior-year quantity.
“As we sit up for the rest of the 12 months, we’re working beneath the next assumptions. We anticipate the working surroundings to stay difficult. We don’t anticipate an enchancment within the U.S. retail surroundings. And eventually, we anticipate script quantity progress to stay muted and anticipate continued pressures on pharmacy margins. In mild of those elements, we’re decreasing our outlook. We now anticipate to ship adjusted earnings per share of $2.80 to $2.95 for the fiscal 12 months 2024,” mentioned Walgreens’ CEO Tim Wentworth throughout the Q3 earnings name.
Walgreens’ inventory has been languishing under its 12-month common for round 5 months. After dropping a dismal 54% up to now six months, the shares traded barely larger on Monday afternoon.
